TransMed7
Accuracy - the Crucial Factor
Accuracy — with Precision, Control, Effortless Penetration, Capture, Transport — the hummingbird is nature’s most skillful surgeon. TransMed7’s Zero5 technology leverages these principles to unlock the power of repeatable access to every area of the body to remove, reveal, deliver or replace. Enter the new frontier.

Zero5

Zero 5
- zero dead space
- zero collateral tissue displacement
- zero limitations on sample length
- zero restrictions on tissue density
- zero sample structure distortion

SpeedBird

SpeedBird
SpeedBird is TransMed7's application of Zero5 technology to handheld, ultrasound guided soft tissue biopsy for the field of breast health
- Forward Coring
- Minimally traumatic
- Single insertion, multiple collection (SIMC)
- Ease of use
- Consistent, reproducible, high quality samples
- Cost effective

Concorde

Concorde
Concorde is TransMed7's application of Zero5 technology to stereotactic / 2D-3D tomosynthesis or ultrasound guided soft tissue biopsy for the field of breast health
- Forward or combined Forward and Side coring action
- Familiar sampling "around the clock" procedure
- Unlimited access
- Ability to sample multiple targets
- No console needed
- Accuracy with concordance for high quality samples
- Gentle action for Patient comfort
- Single Insertion-Multiple Collection (SIMC)
- Minimal Set-up and Waste

Cardinal

Cardinal
Cardinal is TransMed7’s application of Zero5 technology to true Fine Needle Core Biopsy (FNCB) for lymph node, thyroid, liver, pancreas and kidney biopsies.
ABOUT
A World Of Biopsy Challenges. One Solution - TransMed7’s Zero5 Technology
TransMed7’s instruments are designed knowing that space occupying lesions are most effectively treated at their earliest stages -- microscopic levels in most cases. They are also designed with the anticipation of advances in several areas including micro-imaging, genomic profiling, neoadjuvant therapies and earlier detection with increasing access to these important advances for patients around the world.
TransMed7’s solution is to maximize the benefits of these trends with instruments that can be scaled down in caliber to match micro-imaging sizes, streamlined in their profile to gently penetrate and capture the essential information needed for diagnosis to minimize tissue damage, and simplified in their construction to lower costs so that they are affordable in every economy in the world.

Who We Are And What We Do

TransMed7 is a privately-held medical technology company founded in 2010 to generate transformational technologies for diverse fields of healthcare around the world.
We are focused on the highly efficient development of innovative, cost effective, minimally invasive medical devices via several project companies with a particular focus in oncologic, regenerative, and cardiovascular disease.
Our products are designed to address critical healthcare needs in medical fields such as: breast health; soft tissue surgery, including small or fragile tissues and difficult to access areas; endoscopy, laparoscopy, robotics applications; bone marrow biopsy and harvest; interventional cardiology; and minimally invasive peripheral vascular procedures.
News & Announcements
TransMed7, LLC Announces First Revenue from Concorde Family of Devices
TransMed7, LLC Announces First Clinical Use of VacuPac®, a New Self-Contained, Vacuum-Assist Attachment for all of its Vacuum-Assisted, Single Insertion - Multiple Collection (SIMC®) Platforms of Biopsy Devices
TransMed7, LLC Announces First Clinical Cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch
TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch
TransMed7, LLC Announces First Clinical Use of SpeedBird™ Breast Biopsy Devices for Commercial Launch
TransMed7, LLC Announces First Results from Clinical Use of its Vacuum-Assisted, Single Insertion - Multiple Collection (SIMC™) Platform of Breast Biopsy Devices

Want to Know More?
please reach out to us using the form below.